Replicating oncolytic viruses: An overview

Expert Opinion on Investigational Drugs

Volumn 5, Issue 6, 1996, Pages 753-762

  Kirn, David H ^a,b  

^a ONYX PHARMACEUTICALS   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0000871794     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.5.6.753     Document Type: Review

References (40)

1. DOCK G: Am. J. Med. Sci. (1904) 127:563.
2. SOUTHAM CM, MOORE AE: Clinical studies of viruses as antineoplastic agents, with particular reference to Egypt 101 virus. Cancer (1952) 5:1025-1034.
3. WEBB HE, SMITH CE: Viruses In the treatment of cancer. Lancet (1970) 1(658):1206-1208.
4. SMITH R, HUEBNER RJ, ROWE WP, SCHATTEN WE, THOMAS LB: Studies on the use of viruses in the treat ment of carcinoma of the cervix. Cancer(1956) 9:1211 1218.
5. ASAD AT: Treatment of human cancer with mumps virus. Cancer (1974) 34(6):1907-1928.
6. ZINKERNAGEL RM: Immunology taught by viruses. Science (1996) 271(5246):173-178. (Pubitemid 26033295)
7. SOUTHAM CM: Present status of oncolytic virus studies. NY. Acad. Sci. (1960):656-673
8. MOUSSET S, OUADRHIRI Y, CAILLET-FAUQUET P, ROM-MELAERE J: The cytotoxicity of the autonomous parvo virus minute virus of mice nonstructural proteins In FR3T3 rat cells depends on oncogene expression. J. Virol. (1994) 68(10):6446-6453. (Pubitemid 24294894)
9. LORENCE RM, ROOD PA, KELLEY KW: Newcastle disease virus as an antineoplastic agent: induction of tumour necrosis factor-alpha and augmentation of Its cytotoxic ity. J. Natl. Cancer Inst. (1988) 80(l6):1305-1312.
10. GOODING LR: Regulation of TNF-mediated cell death and Inflammation by human adenoviruses. Infect. Agents Dis. (1994) 3(2-3):106-115. (Pubitemid 24280989)
11. JIA WW, MCDERMOTT M, GOLDIE J et al.: Selective de struction of gliomas in immunocompetent rats by thymidine klnase-defective herpes simplex virus type I [see comments]. J. Natl. Cancer Inst. (1994) 86(16):1209-1215. (Pubitemid 24253695)
12. CASSEL WA, GARRETT RE: Tumour immunity after viral oncolysis. J. Bacteriol. (1966) 92(3):792.
13. CASSEL WA, MURRAY DR: A ten-year follow-up on stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate. Med. Oncol. TumourPharmacother. (1992) 9(4):l69-171. (Pubitemid 23122622)
14. MARTUZA RL, MALICK A, MARKERT JM, RUFFNER KL, COEN DM: Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science (1991) 252(5007):854-856. (Pubitemid 121000529)
15. MARKERT JM, COEN DM, MALICK A, MINETA T, MARTUZA RL: Expanded spectrum of viral therapy in the treatment of nervous system tumours. J. Neurosurg. (1992) 77(4):590-594.
16. MARKERT JM, MALICK A, COEN DM, MARTUZA RL: Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir. Neurosurgery (1993) 32(4):597-603. (Pubitemid 23099525)
17. MINETA T, RABKIN SD, YAZAKIT, HUNTER WD, MARTUZA RL: Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nature Medicine (1995) 1(9):938-943.
18. CHOU J, KERN ER, WHITLEY RJ, ROIZMAN B: Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth In culture. Science (1990) 250(4985):1262-1266. (Pubitemid 120031840)
19. FLANAGAN AD, LOVE R, TESAR W: Propagation of Newcastle disease virus in Ehrlich ascites cells in vitro and in vivo. Proc. Soc. Exp. Biol. Med. (1995) 90:82-86.
20. REICHARD KW, LORENCE RM, CASCINO CJ et al: Newcastle disease virus selectively kills human tumour cells. J. Surg Res. (1992) 52(5):448-453.
21. CASSEL WA, GARRETT RE: Newcastle disease virus as an antineoplastic agent. Cancer (1965) 18(7) :863-868.
22. LORENCE RM, REICHARD KW, KATUBIG BB et al: Complete regression of human neuroblastoma xenografts in athymic mice after local Newcastle disease virus therapy [see comments]. J. Natl. Cancer Inst. (1994) 86(16):1228-1233. (Pubitemid 24253698)
23. CASSEL WA, MURRAY DR, PHILLIPS HS: A Phase O study on the postsurgical management of Stage n malignant melanoma with a Newcasue disease virus oncolysate. Cancer (1983) 52(5):856-860. (Pubitemid 13037651)
24. TOOLAN HW, RHODE SLD, GIERTHY JF: Inhibition of 7,12-dimethylbenz(a) anthracene-induced tumours in Syrian hamsters by prior infection with H-1 parvovirus. Cancer Res. (1982) 42(7):2552-2555. (Pubitemid 12085708)
25. ROMMELAERE J, CORNELIS JJ: Antineoplastic activity of parvoviruses. J. Virol. Methods(1991) 33(3):233-251.
26. DUPRESSOIR T, VANACKER JM, CORNELIS JJ, DUPONCHEL N, ROMMELAERE J: Inhibition by parvovirus H-l of the formation of tumours in nude mice and colonies in vitro by transformed human mammary epithelial cells. Cancer Res. (1989) 49(12):3203-3208. (Pubitemid 19162125)
27. GUETTA E, GRAZIANAI Y, TAL J: Suppression of Ehrlich ascites tumours in mice by minute virus of mice. J. Natl. Cancer Inst. (1986) 76(6):1177-1180. (Pubitemid 16093153)
28. TELERMAN A, TUYNDER M, DUPRESSOIR T et al.: A model for tumour suppression using H-l parvovirus. Proc. Natl. Acad. Sci. USA (1993) 90(18):8702-8706. (Pubitemid 23277738)
29. DUPONT F, TENEBAUM L, GUO LP et al: Use of an autonomous parvovirus vector for selective transfer of a foreign gene into transformed human cells of different tissue origins and its expression therein. J. Virol. (1994) 68(3):1397-1406. (Pubitemid 24065701)
30. OP DE BEECK A, ANOUJA F, MOUSSET S, ROMMELAERE J, CAILLET-FAUQUET P: The nonstructural proteins of the autonomous parvovirus minute virus of mice interfere with the cell cycle, inducing accumulation in G2. Cell Growth Differ. (1995) 6(7):781-787.
31. VAN PACKTERBEKE C, TUYNDER M, COSYN JP et al: Parvovirus H-l inhibits growth of short-term tumour-derived but not normal mammary tissue cultures. Int. J. Cancer(1993) 55(4):672-677. (Pubitemid 23328958)
32. BARKER DD, BERK AJ: Adenovirus proteins from boui E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology (1987) 156:107-121. (Pubitemid 17013653)
33. YANG Y, NUNES FA, BERENCSIK etal: Cellular immunity to viral antigens limits El-deleted adenoviruses for gene therapy. Proc. Natl. Acad. Sci. USA(1994) 91, (10):4407-4411. (Pubitemid 24143442)
34. DAY DB, ZACHARIADES NA, GOODING LR: Cytolysis of adenovirus-infected murine fibroblasts by IEN-gamma-primed macrophages is TNF-and contact-dependent. Cell Immunol. (1994) 157(1):223-238. (Pubitemid 24259466)
35. HERMISTON TW, TRIPP RA, SPARER T, GOODING LR, WOLD WS: Deletion mutation analysis of the adenovirus type 2 E3-gpl9K protein: identification of sequences within the endoplasmic reticulum lumenal domain that are required for class I antigen binding and protection from adenovirus-specific cytotoxic T-lymphocytes. J. Virol. (1993) 67(9):5289-5298. (Pubitemid 23241360)
36. YANG Y, TRINCHIEREI G, WILSON JM: Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene ther-apy to mouse lung [see comments]. Nature Medicine (1995) l(9):890-893.
37. GINSBERG HS, PRINCE GA: The molecular basis of adenovirus pathogenesis. Infect. AgentsDis. (1994) 3(1):1-8. (Pubitemid 24234128)
38. JAIN RK: Barriers to drug delivery in solid tumours. Sci. Am. (1994) 271(l):58-65.
39. DVORAK HF, NAGY JA, DVORAK JT, DVORAK AM: Identification and characterization of the blood vessels of solid tumours that are leaky to circulating macromole-cules. Am. J. Pathol. (1988) 133(1):95-109.
40. YUAN F, DELLIAN M, FUKUMURA D et ah. Vascular permeability in a human tumour xenograft: molecular size dependence and cutoff size. Cancer Res. (1995) 55(17):3752-3756.